CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives

Mohamad Mohty, Jordan Gautier, Florent Malard, Mahmoud Aljurf, Ali Bazarbachi, Christian Chabannon, Mohamed A. Kharfan-Dabaja, Bipin N. Savani, He Huang, Saad Kenderian, Arnon Nagler, Miguel Angel Perales

Research output: Contribution to journalReview articlepeer-review

23 Scopus citations

Abstract

The approval of tisagenlecleucel and axicabtagene ciloleucel represents a breakthrough in the field of immune and cellular therapy for hematologic malignancies. These anti-CD19 chimeric antigen receptor-T cells (CAR) proved to be highly effective in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL) and specific histologic subtypes of B-cell non-Hodgkin lymphomas. This expert review aims to summarize the current available research evidence in this field, with a special focus on the different challenges faced by treating physicians, and we also provide future perspectives.

Original languageEnglish (US)
Pages (from-to)2767-2778
Number of pages12
JournalLeukemia
Volume33
Issue number12
DOIs
StatePublished - Dec 1 2019

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'CD19 chimeric antigen receptor-T cells in B-cell leukemia and lymphoma: current status and perspectives'. Together they form a unique fingerprint.

Cite this